STAT+: Anthropic’s Claude Science is coming for Kendall Square

STAT PlusBiotech Anthropic’s Claude Science is coming for Kendall Square The biomedical ecosystem in Cambridge, Mass., and Boston have a tremendous amount at stake Manage alerts for this article Email this article Share this article By Robert Weisman — Boston GlobeJuly 14, 2026 This is the year artificial intelligence has emerged in the public square as a full-fledged bogeyman. College grads boo commencement speakers who invoke AI as the modern equivalent of “plastics,” the career advice given to Dustin Hoffman’s character in the 1967 film “The Graduate.” Workers recoil when companies wield it as a cost-cutting, job-slashing sword. Even a wary Pope Leo XIV warns against the fusion of AI into nuclear war-fighting systems.Advertisement So this month’s low-key unveiling of Claude Science, an app that adapts Anthropic’s large language model for biopharma research labs, was a timely reminder that AI still has the potential to do more than reduce corporate head counts and endanger civilization. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Artificial intelligence, biotechnology, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Robert Weisman — Boston Globe Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout July 14, 2026 STAT Plus: Akero team, backed by Fairmount, launches new immunology company Breaking News July 14, 2026 STAT Plus: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows Advertisement Biotech July 14, 2026 STAT Plus: Drug metabolism AI competition results show that bigger may not always be better Health July 13, 2026 STAT Plus: Dementia study replicates promising outcomes following risk-reduction strategies The Readout July 13, 2026 STAT Plus: All eyes on data on Biogen’s tau therapy Subscriber Picks